EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Long-Term Outcomes

James K Gabriels, Kristie Coleman, Joanna Fishbein, Gregory Cunn, Alexandra Bekiaridou, Dimitrios Varrias, Nikhil Sharma, Moein Mokhtari, Riya George, Christina Brennan, Amir Gandomi, Sirish Vullaganti und 2 weitere

JACC: Advances · 2026-01 · 5 (1) · 102425

DOI: 10.1016/j.jacadv.2025.102425 ↗

Kurz gefasst

Fachartikel in der Zeitschrift JACC: Advances, 2026-01. Verfasst von James K Gabriels und 13 weiteren Autor:innen. Beteiligte Einrichtung: Northwell Cardiovascular Institute, Center for Arrhythmias, New Hyde Park, New York, USA. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 40 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitieren

Abstract (Originalsprache)

BACKGROUND: Heart failure with preserved ejection fraction (HFpEF) confers a large morbidity and mortality burden. There are no therapies for HFpEF with a proven mortality benefit. OBJECTIVES: The purpose of this study was to evaluate the long-term outcomes of pacing and therapy with beta-blockers in patients with HFpEF. METHODS: In this cohort study, patients admitted to one of 11 hospitals in the Northwell Health system over a 3.5-year period with HFpEF were examined. Beta-blockers use and implantation of a permanent pacemaker (PPM) were examined as exposures. The primary outcome was all-cause mortality, and secondary included any hospital readmission or an emergency department visit. RESULTS: Of the 27,848 patients admitted for HFpEF, 22,308 (52.9% female, mean age 73 ± 14 years) were included in the postdischarge analysis (median follow-up 1.5 years [0.6-2.5 years]). Of the 22,308 patients, 44.3% (9,881/22,308) were discharged on a beta-blockers, 2.5% (547/22,308) had a PPM and were not discharged on a beta-blockers, and 1.7% (380/22,308) were maintained on beta-blockers therapy and also had a PPM. The presence of a PPM at the time of discharge was associated with a 32% lower risk of mortality (HR: 0.68; 95% CI: 0.57-0.80), while discharge on a beta-blockers was associated with a 20% lower risk of mortality (HR: 0.80; 95% CI: 0.72-0.89). CONCLUSIONS: The findings of this large retrospective cohort study suggest that use of beta-blockers and permanent pacing are each associated with a lower risk of mortality in patients with HFpEF.

Schlagwörter

Stichwörter der Autor:innen

beta-blockerheart failure with preserved ejection fractionpermanent pacemaker

Autor:innen und Institutionen

  • Northwell Cardiovascular Institute, Center for Arrhythmias, New Hyde Park, New York, USA.
  • Office of Academic Affairs, New Hyde Park, New York, USA.
  • Northwell Cardiovascular Institute, Center for Arrhythmias, New Hyde Park, New York, USA. Electronic address: smountanto@northwell.edu.

Zitieren

APA

Gabriels, J. K., Coleman, K., Fishbein, J., Cunn, G., Bekiaridou, A., Varrias, D., Sharma, N., Mokhtari, M., George, R., Brennan, C., Gandomi, A., Vullaganti, S., Epstein, L. M., & Mountantonakis, S. E. (2026). Long-Term Outcomes. JACC: Advances, 5(1), 102425. https://doi.org/10.1016/j.jacadv.2025.102425

Vancouver

Gabriels JK, Coleman K, Fishbein J, Cunn G, Bekiaridou A, Varrias D, et al. Long-Term Outcomes. JACC: Advances. 2026;5(1):102425. doi:10.1016/j.jacadv.2025.102425

BibTeX
@article{Gabriels2026,
  author = {Gabriels, James K and Coleman, Kristie and Fishbein, Joanna and Cunn, Gregory and Bekiaridou, Alexandra and Varrias, Dimitrios and Sharma, Nikhil and Mokhtari, Moein and George, Riya and Brennan, Christina and Gandomi, Amir and Vullaganti, Sirish and Epstein, Laurence M and Mountantonakis, Stavros E},
  title = {Long-Term Outcomes},
  journal = {JACC: Advances},
  year = {2026},
  volume = {5},
  number = {1},
  pages = {102425},
  doi = {10.1016/j.jacadv.2025.102425}
}
Kostenlos starten →